There has been notable progress on the clinical trial front this week. Our reporters break down what it all means
Hannah Kuchler, Clive Cookson, Anna Gross
Several potential Covid-19 vaccines have hit significant progress markers in the past two weeks. To be sure, there’s still a long way to go in the coronavirus fight — especially with infection counts at record highs around the world — but there are signs of a light at the end of the tunnel, even if it is some way down the road.
On Monday, Oxford and AstraZeneca published promising results from the first phase of its vaccine clinical trials in the The Lancet medical journal, and last week phase-one vaccine trials conducted by Moderna of the US led to positive antibody responses. Vaccines developed by CanSino Biologics and Pfizer and BioNTech also showed good signs of provoking a dual T-cell response.
But what do these results mean for the viability of a vaccine? How do the different phases of vaccine development differ? When are shots actually going to be distributed and who will get them first? And how long will vaccines provide immunity? Many questions surround a future would-be vaccine.
Hannah Kuchler, US pharmaceutical correspondent; Clive Cookson, science editor; and Anna Gross, science and environment reporter, will be answering your questions in the comments throughout the day.
Hannah can answer questions about vaccine development in the US. Clive can speak to what is being researched and discussed in the scientific community. And Anna can share her expertise in the science behind immunity and how a vaccine would work.
All three have been closely following the progress of potential vaccines and treatments. Drop your questions in the comments below and Hannah, Clive and Anna will be answering them throughout the day.